|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
Q2 FY2021
As of Jun 30, 2021
|
Q1 FY2021
As of Mar 31, 2021
|
Q4 FY2020
As of Dec 31, 2020
|
Q3 FY2020
As of Sep 30, 2020
|
Q2 FY2020
As of Jun 30, 2020
|
Q1 FY2020
As of Mar 31, 2020
|
Q3 FY2019
As of Sep 30, 2019
|
Q2 FY2019
As of Jun 30, 2019
|
Q1 FY2019
As of Mar 31, 2019
|
Q4 FY2018
As of Dec 31, 2018
|
Q3 FY2018
As of Sep 30, 2018
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Restricted cash (includes restricted cash of consolidated VIEs of $24,613 and $20,177 as of September 30, 2023 and December 31, 2022, respectively) | ||||||||||||||||||||
| Gross loans receivable (includes loans of consolidated VIEs of $1,394,957 and $1,294,706 as of March 31, 2022 and December 31, 2021, respectively) | ||||||||||||||||||||
| Gross loans receivable (includes loans of consolidated VIEs of $1,165,529 and $1,130,837 as of September 30, 2023 and December 31, 2022, respectively) | ||||||||||||||||||||
| Less: Allowance for credit losses (includes allowance for credit losses of consolidated VIEs of $185,669 and $67,609 as of September 30, 2023 and December 31, 2022, respectively) | ||||||||||||||||||||
| Loans receivable, net | ||||||||||||||||||||
| Income taxes receivable | ||||||||||||||||||||
| Prepaid expenses and other (includes prepaid expenses and other of consolidated VIEs of $16 and $5,069 as of September 30, 2023 and December 31, 2022, respectively) | ||||||||||||||||||||
| Property and equipment, net | ||||||||||||||||||||
| Investment in Katapult | ||||||||||||||||||||
| Right of use asset - operating leases | ||||||||||||||||||||
| Deferred tax assets (includes deferred tax assets of consolidated VIEs of $99 and $3,735 as of September 30, 2023 and December 31, 2022, respectively) | ||||||||||||||||||||
| Goodwill and intangibles, net | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Intangibles, net | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Assets held for sale | ||||||||||||||||||||
| Assets, discontinued operations | ||||||||||||||||||||
| Total Assets | ||||||||||||||||||||
| LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY | ||||||||||||||||||||
| Liabilities | ||||||||||||||||||||
| Accounts payable and accrued liabilities (includes accounts payable and accrued liabilities of consolidated VIEs of $3,006 and $6,704 as of September 30, 2023 and December 31, 2022, respectively) | ||||||||||||||||||||
| Deferred revenue | ||||||||||||||||||||
| Deferred revenue (includes deferred revenue of consolidated VIEs of $14 and $31 as of September 30, 2023 and December 31, 2022, respectively) | ||||||||||||||||||||
| Lease liability - operating leases | ||||||||||||||||||||
| Contingent consideration related to acquisition | ||||||||||||||||||||
| Income taxes payable | ||||||||||||||||||||
| Accrued interest (includes accrued interest of consolidated VIEs of $8,284 and $7,023 as of September 30, 2023 and December 31, 2022, respectively) | ||||||||||||||||||||
| Liability for losses on CSO lender-owned consumer loans | ||||||||||||||||||||
| Debt (includes Debt and related issuance costs of consolidated VIEs of $979,500 and $14,428 as of December 31, 2021 and $147,427 and $7,766 as of December 31, 2020, respectively) | ||||||||||||||||||||
| Debt (includes debt and issuance costs of consolidated VIEs of $1,101,912 and $12,983 as of March 31, 2022 and $979,500 and $14,428 as of December 31, 2021, respectively) | ||||||||||||||||||||
| Debt (includes debt and issuance costs of consolidated VIEs of $897,720 and $11,979 as of September 30, 2023 and $878,103 and $13,428 as of December 31, 2022, respectively) | ||||||||||||||||||||
| Other long-term liabilities | ||||||||||||||||||||
| Deferred tax liabilities | ||||||||||||||||||||
| Liabilities, discontinued operations | ||||||||||||||||||||
| Total Liabilities | ||||||||||||||||||||
| Stockholders' (Deficit) Equity | ||||||||||||||||||||
| Preferred stock - $0.001 par value, 25,000,000 shares authorized; no shares were issued | ||||||||||||||||||||
| Common stock - $0.001 par value; 225,000,000 shares authorized; 50,998,655 and 50,216,165 shares issued; and 41,300,542 and 40,518,052 shares outstanding at the respective period ends | ||||||||||||||||||||
| Treasury stock, at cost - 9,698,113 shares at the respective period ends | ||||||||||||||||||||
| Paid-in capital | ||||||||||||||||||||
| (Accumulated deficit)/retained earnings | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Total Stockholders' Deficit | ||||||||||||||||||||
| Total Liabilities and Stockholders' (Deficit) Equity | ||||||||||||||||||||
Loading...
